Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 8.2%

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price was up 8.2% during mid-day trading on Tuesday . The stock traded as high as $9.28 and last traded at $9.28. Approximately 99,331 shares were traded during trading, a decline of 45% from the average daily volume of 179,014 shares. The stock had previously closed at $8.58.

Pulse Biosciences Price Performance

The business has a 50-day simple moving average of $8.05 and a 200 day simple moving average of $8.69. The firm has a market cap of $659.94 million, a PE ratio of -14.75 and a beta of 1.73.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.21) earnings per share for the quarter.

Insider Transactions at Pulse Biosciences

In related news, CEO Burke Thomas Barrett acquired 10,000 shares of the business’s stock in a transaction on Monday, May 20th. The stock was acquired at an average cost of $8.56 per share, with a total value of $85,600.00. Following the acquisition, the chief executive officer now directly owns 10,000 shares in the company, valued at approximately $85,600. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 71.50% of the company’s stock.

Institutional Trading of Pulse Biosciences

Hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD bought a new stake in Pulse Biosciences in the first quarter worth $88,000. Vanguard Group Inc. grew its position in Pulse Biosciences by 28.8% in the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after acquiring an additional 189,227 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after acquiring an additional 2,952 shares during the last quarter. Inspire Investing LLC raised its position in Pulse Biosciences by 32.1% during the first quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock valued at $360,000 after purchasing an additional 10,039 shares during the period. Finally, PNC Financial Services Group Inc. bought a new position in shares of Pulse Biosciences during the 4th quarter valued at approximately $242,000. 76.95% of the stock is owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.